3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Emily Reiser of Texas Medical Center Innovation, Atul Varadhachary of Fannin Innovation Studio, and Vicki Knott of Crux OCM. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to two local innovators, as well as one honorary Houstonian, across industries — energy, health care, and more — recently making headlines in Houston innovation.

Emily Reiser, senior manager for innovation community and engagement for Texas Medical Center Innovation

Emily Reiser joins the Houston Innovators Podcast to discuss the latest at TMC Innovation. Photo courtesy of TMC Innovation

Over her past few years at Texas Medical Center Innovation, Emily Reiser has worked with over 1,000 startups. So, it's safe to say she knows what a good pitch looks like and what health tech startups need as far a support from mentors and experts goes.

She shares some of her advice and observations on this week's episode of the Houston Innovators Podcast. She also explains how TMC Innovation is uniquely positioned to advance the best and brightest in life science innovation.

"When we think about how a startup is going to be successful, we think about how they are going to build new partnerships. But we also think about all the people they're going to need to activate and bring them to the next level," Reiser says. "What we do is curate a community of high-value resources that can help these companies elevate to that next level." Click here to read more.

Atul Varadhachary, managing partner of Houston's Fannin Innovation Studio

Atul Varadhachary, managing partner of Fannin Innovation Studio, says that now is the time to invest in life sciences. Photo via fannininnovation.com

Fannin Innovation Studio is hard at work finding, supporting, and accelerating life science innovations, but, according to Managing Partner Atul Varadhachary, the organization can be doing so much more — if only the budget allowed.

Varadhachary makes a case for tripling or even quadrupling the number of participants in Fannin's federally accredited fellowship program. He says this one relatively small investment could push Houston closer to Boston in the life sciences stratosphere.

"I can think of nothing that could give a bigger return on investment for the city," Varadhachary says of expanding Fannin's fellowship program. Click here to read more.

Vicki Knott, co-founder and CEO of Crux OCM

A Canadian software company is expanding its presence in Houston to meet the needs of its clients. Photo courtesy of Crux OCM

For six months of the year, Vicki Knott plans to take up residence in Houston. As the co-founder and CEO of Calgary-based Crux OCM, Knott saw a big opportunity to expand her control room operations automation software business — especially when she nabbed Houston-based Phillips 66 as a client.

Calgary and Houston have a lot in common, Knott says, and she sees a very natural connection to the two regions. Knott plans to work six months of the year in Houston with the local office.

"A lot of the companies that head offices in Houston, they have head offices in Calgary," she says. "If a startup in Houston is getting traction, I think there's a natural movement to start in the Calgary market and vice versa." Click here to read more.

Atul Varadhachary, managing partner of Fannin Innovation Studio, says that now is the time to invest in life sciences. Photo via Getty Images

Innovation studio aims to put Houston on the map for life science startup development

fostering innovation

In a report last year from commercial real estate services company JLL, Boston took the crown for hosting the country's top life sciences ecosystem. Houston ranked 11th.

The difference between Houston and Boston "is not the innovation, it's not the technology, it's not the money. It's that we don't have experienced life sciences entrepreneurs," says Dr. Atul Varadhachary, managing partner of Houston's Fannin Innovation Studio, a for-profit entity that commercializes biotech and medtech concepts.

Fannin has tried to replicate Boston's robust life sciences ecosystem "in a really, really tiny way" via its fellowship program, Varadhachary says. But the reach of the program could be even greater, he believes.

Varadhachary makes a case for tripling or even quadrupling the number of participants in Fannin's federally accredited fellowship program. He says this one relatively small investment could push Houston closer to Boston in the life sciences stratosphere.

Atul Varadhachary is the managing partner of Houston's Fannin Innovation Studio. Photo via fannininnovation.com

To be sure, Houston is no slouch in life sciences. For instance, commercial real estate services company CBRE issued a report last fall ranking Houston second among the country's top emerging clusters for life sciences. But cities like Boston, San Francisco, and San Diego still reign as life sciences royalty in the U.S.

Fannin typically taps five people at a time — folks who've recently earned a master's degree, medical degree or PhD — for a two-year fellowship in life sciences entrepreneurship and commercialization. The initiative is comparable to a post-doctorate program in research or medicine. The Fannin fellows collaborate with therapeutics and medical device companies in the studio's portfolio, gaining hands-on training in facets of business like R&D, intellectual property, regulatory matters, and financing.

Today, five fellows and seven interns work at Fannin. The fellowship program launched in 2006; the internship program started a year earlier. In all, Fannin has welcomed more than 250 fellows and interns. Some of them have gone on to work at Houston organizations such as TMC Innovation, MD Anderson Cancer Center, and the University of Houston.

Varadhachary believes boosting the fellowship headcount to perhaps 15 instead of the current five would be a small price to pay to help elevate Houston's status in life sciences. The full cost of each fellowship is less than $100,000 a year, so bringing aboard another 10 fellows would require an extra annual commitment of under $1 million. That kind of money isn't in Fannin's budget, though.

"I can think of nothing that could give a bigger return on investment for the city," Varadhachary says of expanding Fannin's fellowship program.

More fellows would mean more entrepreneurs equipped to run or start life sciences businesses in Houston, he says. Varadhachary acknowledges the value of efforts like the soon-to-open TMC3 life sciences hub and the recently opened Ion entrepreneurship hub, but he'd like to see more emphasis placed on nurturing people and not just startups.

Varadhachary says the "the one single thing" that Houston could do to increase its probability of success in life sciences, particularly in therapeutics, would be to crank up cultivation of entrepreneurial talent.

"By and large, I don't think know that this community appreciates how important and how under-resourced that whole people-development piece is," he says. "It's not something that comes from taking classes or watching. It comes from doing."

Andrea Letkeman, director of professional development at Fannin, says the fellows initially work one-on-one with a senior executive on projects, then eventually graduate to running their own projects. Fellows also get a close-up look at other projects underway at Fannin.

Varadhachary wants to get Fannin fellows excited "about what we're doing in Houston, and then give them an opportunity to be part of our ecosystem."

Some Fannin fellows have been hired on a full-time basis by the studio, or they've moved into jobs at venture capital firms, life sciences startups, or other players in the ecosystem, according to Letkeman. She says the fellows lend "energy and vibrancy" to Fannin.

"I think that the Fannin model is fairly unique for Houston. There are models that are similar, across the country, to what we do. But there's not enough of them, quite frankly, for the number of people that are interested in these kinds of roles," Letkeman says.

"There is talent that is looking for a way to bridge the gap between academia and real-world commercialization," she adds. "There's just not enough opportunities out there for them."

Re:3D is one of two Houston companies to be recognized by the SBA's technology awards. Photo courtesy of re:3D

2 Houston startups win national technology award from SBA

winner, winner

A couple of Houston startups have something to celebrate. The United States Small Business Administration announced the winners of its Tibbetts Award, which honors small businesses that are at the forefront of technology, and two Houston startups have made the list.

Re:3D, a sustainable 3D printer company, and Raptamer Discovery Group, a biotech company that's focused on therapeutic solutions, were Houston's two representatives in the Tibbetts Award, named after Roland Tibbetts, the founder of the SBIR Program.

"I am incredibly proud that Houston's technology ecosystem cultivates innovative businesses such as re:3D and Raptamer. It is with great honor and privilege that we recognize their accomplishments, and continue to support their efforts," says Tim Jeffcoat, district director of the SBA Houston District Office, in a press release.

Re:3D, which was founded in 2013 by NASA contractors Samantha Snabes and Matthew Fiedler to tackle to challenge of larger scale 3D printing, is no stranger to awards. The company's printer, the GigaBot 3D, recently was recognized as the Company of the Year for 2020 by the Consumer Technology Association. Re:3D also recently completed The Ion Smart and Resilient Cities Accelerator this year, which has really set the 20-person team with offices in Clear Lake and Puerto Rico up for new opportunities in sustainability.

"We're keen to start to explore strategic pilots and partnerships with groups thinking about close-loop economies and sustainable manufacturing," Snabes recently told InnovationMap on the Houston Innovators Podcast.

Raptamer's unique technology is making moves in the biotech industry. The company has created a process that makes high-quality DNA Molecules, called Raptamers™, that can target small molecules, proteins, and whole cells to be used as therapeutic, diagnostic, or research agents. Raptamer is in the portfolio of Houston-based Fannin Innovation Studio, which also won a Tibbetts Award that Fannin Innovation Studio in 2016.

"We are excited by the research and clinical utility of the Raptamer technology, and its broad application across therapeutics and diagnostics including biomarker discovery in several diseases, for which we currently have an SBIR grant," says Dr. Atul Varadhachary, managing partner at Fannin Innovation Studio.

This year, 38 companies were honored online with Tibbetts Awards. Since its inception in 1982, the awards have recognized over 170,000 honorees, according to the release, with over $50 billion in funding to small businesses through the 11 participating federal agencies.

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Houston biotech startup raises millions to battle pediatric cancer

fresh funds

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Pulmotect, a clinical-stage biotechnology company based in Houston, is testing a drug that could be useful in mitigating the threats of the coronavirus, which is currently been recognized as a global health emergency. Getty Images

Houston biotech company is creating a drug that could fight the coronavirus

Med tech

A drug being developed by a Houston biopharmaceutical company eventually could help combat what the World Health Organization has proclaimed a global health emergency.

Experiments conducted by clinical-stage biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

In the Galveston experiments, a single inhaled dose of PUL-042 protected lab mice from the SARS virus, and it greatly reduced the amount of virus in their lungs after the mice became infected with SARS or MERS.

"With the risks of virulent coronaviruses and other threats increasing, as shown by the recent outbreak in Wuhan that has already spread from China to other countries including the United States, Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of current and emerging pathogens and protecting vulnerable populations," says CEO Dr. Colin Broom in a news release.

The ability of PUL-042 to ward off the newest type of coronavirus, 2019-nCoV, hasn't been tested yet. However, the drug eventually could help prevent the new virus from spreading, says Broom, who joined Pulmotect as CEO last fall. A separate study would be required to evaluate PUL-042 in patients exposed to 2019-nCoV, he says.

"PUL-042 has the potential to prevent and treat respiratory complications in many high-risk patient populations, including those where no effective therapies are currently available, as is the case with the current coronavirus outbreak," Brenton Scott, president and chief operating officer of Pulmotect, says in the release.

Since its discovery in late December 2019 in Wuhan, China, nearly 9,800 people around the world were infected with 2019-nCoV as of January 31, The New York Times reported. Of those people, more than 200 died. On January 30, the World Health Organization (WHO) declared the virus outbreak a global health emergency.

No specific treatment or cure for 2019-nCoV virus is available. This virus is among seven known coronaviruses.

Symptoms of the Wuhan coronavirus include fever, cough, and shortness of breath, according to the U.S. Centers for Disease Control and Prevention (CDC). The virus can cause pneumonia, SARS, kidney failure, or even death, the Virginia Department of Health says.

PUL-042 "would be a great tool to have available for future outbreaks and epidemics, in addition to being used more routinely for more common infections," Broom says.

Fighting coronaviruses is a potential byproduct of PUL-042.

Initially, Pulmotect is focusing development of PUL-042 on the prevention and treatment of respiratory complications suffered by cancer patients with suppressed immune systems. Phase 1 clinical trials already have taken place in the U.S., and Phase 2 clinical trials are scheduled for later this year.

A separate trial of PUL-042 is underway in London. There, the drug is being tested on patients with chronic obstructive pulmonary disease (COPD) who are prone to lung infections. COPD is an inflammatory disease that blocks airflow from the lungs. People with COPD face a heightened risk of conditions like heart disease and lung cancer, the Mayo Clinic says.

Broom says PUL-042 is a few years away from being considered for approval by the U.S. Food and Drug Administration (FDA).

To date, Pulmotect has raised more than $28 million in outside funding. Founded in 2007, Pulmotect emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

Patents for PUL-042, invented by MD Anderson Cancer Center and Texas A&M University, have been issued in nine countries.

A TMCx company has raised money in Houston, UH's online program named best in the nation, and more Houston innovation news. Courtesy of TMCx

TMCx company receives investment from Houston VC, UH program recognized, and more innovation news

short stories

Houston's innovation ecosystem has seen a busy January so far — the city has claimed a unicorn in High Radius, The Ion has named a series of new execs, and so much more.

Given this influx of news, you might've missed some other Houston innovation headlines, like UH being recognized for its online master's program, recent fundings, and Texas being named a state for female entrepreneurs. Here's a few short stories to catch you up.

Texas Halo Fund invests in TMCx company

Photo via kegg.tech

A medical device company that focuses on keeping its female users in control of their fertility health just received an investment from a Houston venture capital firm.

Texas Halo Fund invested $200K in kegg, a San Francisco-based startup that participated in the Texas Medical Center's TMCx09 cohort. The device is an easy-to-use fertility tracker that easily analyzes cervical fluid to help detect a woman's ovulation up to 7 days in advance. Kegg pairs with a smartphone app to inform and track the user's fertility.

"kegg appeals to us for many reasons. We believe the FemTech space is growing and that women are looking take charge of their fertility. There is an increased desire to have insights into one's health and understanding trends in fertility is a natural progression, says Kyra Doolan, managing Director at Texas Halo Fund, in a news release.

"We've been impressed by the company's CEO Kristina Cahojova and how far she's taken the company with a limited budget. We look forward to seeing the product hit the consumer market."

University of Houston recognized for online graduate program

Photo courtesy of University of Houston

The University of Houston's College of Education's online master's degree programs have been recognized by U.S. News & World Report as among the top in the nation.

The college ranked No. 8 for its program in a ranking that factored in student engagement, technology tools, surveys of deans, faculty credentials, and student excellence, according to a news release from UH.

"Our faculty and staff strive to give students a top-notch experience online," says Bob McPherson, dean of the UH College of Education, in the news release. "We work to emphasize high-quality instruction and support while allowing students the flexibility and personalization of an online learning environment."

UH's program tied for No. 8 with six other schools, but it's still a huge step up from last year's ranking of No. 19.

Texas ranks No. 5 for female entrepreneurs

Getty Images

According to a new ranking from Fit Small Business, Texas is the fifth best state for female entrepreneurs. The Lone Star State is holding strong in the top tier but slipped from its No. 1 ranking last year.

"High start-up growth, no corporate income tax, and a moderate cost of living are all big pluses for the state, but how does it do regarding a friendly women's business and safety climate?" the report reads. "Well, sort of 'middle-of-the-road,' by the numbers we sourced."

Each state was evaluated by four equally weighted factors: its general business climate and opportunity, the number of female-owned businesses, economic and financial health, and safety and well-being for women. Texas's startup climate and opportunity, which was weighted by 35 percent in the study, was ranked No. 4. When it came to economic and financial health, weighted at 15 percent, Texas also snagged the No. 4 spot.

Rice Business Plan Competition startup raises $1.1 million

Photo via resonado.com

Resonado, the runner-up at the 2019 Rice Business Plan Competition, has raised $1.1 million in funding for its thinner, better-sounding speaker system technology.

The company was founded by four University of Notre Dame University classmates — Brian Cho, Christian Femrite, Erik Perez-Perez, and Peter Moeckel.

Rice University's OWL Investment contributed to the round.

Fannin Innovation Studio makes strategic hire

Praveen Kudithipudi

Photo via fannininnovation.com

Praveen Kudithipudi has been named as director of business development at Houston-based Fannin Innovation Studio. He supports the licensing of Fannin's portfolio technologies as well as collaborations with pharmaceutical companies and academic partners.

"I am excited to have a wonderful opportunity to work at Fannin," says Kudithipudi in the news release. "Fannin builds successful life sciences startups while helping to catalyze the formation of a thriving and sustainable life sciences entrepreneurship ecosystem in Houston. The opportunity to lead licensing, diligence, and collaboration efforts with academic institutions and biotechnology companies here in Houston is truly a unique opportunity."

Kudithipudi received his medical degree in India and specialized in neuroscience in the United Kingdom. He received his MBA from New York University. Prior to this role, he worked in banking, venture capital, and investments in New York.

"We are excited to have someone with the range of experiences and caliber of Praveen on the team," says Atul Varadhachary, Fannin managing partner, in the release. "In our business, we look for high potential technologies at an early stage. Having someone with both a medical background and Wall Street know-how is invaluable to us as we review opportunities and reach out to prospective development partners."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston innovator joins VC world to increase her social impact

Q&A

Kelly Avant didn't exactly pave a linear career path for herself. After majoring in gender studies, volunteering in the Peace Corps, and even attending law school — she identified a way to make a bigger impact: venture capital.

"VC is an awesome way to shape the future in a more positive way because you literally get to wire money to the most innovative thinkers, who are building solutions to the world’s problems," Avant tells InnovationMap.

Avant joined the Mercury Fund team last year as an MBA associate before joining full time as investment associate. Now, after completing her MBA from Rice University this month, Avant tells InnovationMap why she's excited about this new career in investment in a Q&A.

InnovationMap: From law school and the peace corps, what drew you to start a career in the VC world?

Kelly Avant: I graduated from Rice University with an MBA, starting scouting for an investment firm in my first year, and by the summer after my first year I was essentially working full-time interning with Mercury. But, I like to tell people about my undergraduate degree in gender studies and rhetoric from a little ski college in Colorado. If you meet someone else in venture capital with a degree in gender studies, please connect us, but I think I might be the only one. I’ll spare you what I used to think — and say — about business students, but I have really come full circle.

I always thought I would work in a nonprofit space, but after serving in Cambodia with the Peace Corps, working for the National Domestic Violence Hotline, and briefly attending Emory Law School with the intention of becoming a civil rights lawyer.I found that time and time again the root of the problem was a lack of resources. The world’s problems were not going to be solved with my idealism alone.

The problem with operating as a nonprofit in a capitalism is you basically always pandering to the interests of the donors. The NFL was a key sponsor of The National Domestic Violence Hotline. The United States has a complicated, to put it lightly, relationship with Cambodia and Vietnam. It became pretty clear that the donor/nonprofit relationship was oftentimes putting the wrong party in the driver’s seat. I was, and still am, very interested in alternative financing for nonprofits. I became convinced that the most exciting businesses were building solutions to the world’s problems while also turning a profit, which allows them to survive to have a sustainable positive impact.

VC is an awesome way to shape the future in a more positive way because you literally get to wire money to the most innovative thinkers, who are building solutions to the world’s problems.

IM: What are some companies you’re excited about?

KA: There are a couple super interesting founders I’ve met directly engaging with . To name a few: CiviTech, DonateStock, and Polco.

I’m very proud to work on mercury investments like Houston’s own, Topl, which has built an extremely lightweight and energy efficient Blockchain that enables tracking of ethical supply chains from the initial interaction.
I’m also excited about mercury’s investment in Zirtue, which enables relationship based peer to peer lending to solve the massive problem of predatory payday loans.

We have so many awesome founders in our portfolio. The best part about working in VC is meeting passionate innovators every day. I get excited to go to work everyday and help them to build better solutions.

IM: Why are you so passionate about bringing diversity and inclusion into Mercury?

KA: I love working with exciting, highly capable, super smart people. That category includes so many people who have been historically excluded. As an investment team member at Mercury, I do have a voice, and I have an obligation to use that voice to speak highly of the best people in rooms of influence.

IM: With your new role, what are you most focused on?

KA: In my new role, I am identifying and researching high potential investments. We’re building out a Mercury educational series to lift the veil of VC. We want to facilitate a series that gives all founders the basic skills to pass VC due diligence and have the opportunity to build the next innovative companies. My goal is ultimately to produce the best returns possible for our investors, and we can’t accomplish that goal unless we’re building out resources to meet the best founders and help them grow.

------

This conversation has been edited for brevity and clarity.

Houston college system plans to open $30M resiliency-focused center

to the rescue

Houston’s initiative to protect the city from catastrophes is getting a big boost from Houston Community College.

The college is developing the Resilience Center of Excellence to aid the city’s resilience campaign. At the heart of this project is the 65,000-square-foot, $30 million Resiliency Operations Center, which will be built on a five-acre site HCC’s Northeast campus. The complex is scheduled to open in 2024.

HCC estimates the operations center will train about 3,000 to 4,000 local first responders, including police officers and firefighters, during the first three years of operation. They’ll be instructed to prepare for, manage, and respond to weather, health and manmade hazards such as hurricanes, floods, fires, chemical spills, and winter freezes.

According to The Texas Tribune, the operations center will include flood-simulation features like a 39-foot-wide swift water rescue channel, a 15-foot-deep dive area, and a 100-foot-long “rocky gorge” of boulders.

The college says the first-in-the-nation Resilience Center of Excellence will enable residents, employers, civic organizations, neighborhoods, and small businesses to obtain education and certification aimed at improving resilience efforts.

“Our objective is to protect the well-being of our citizens and our communities and increase economic stability,” Cesar Maldonado, chancellor of HCC, said when the project was announced.

Among the programs under the Resiliency Center of Excellence umbrella will be non-credit courses focusing on public safety and rescue, disaster management, medical triage, and debris removal.

Meanwhile, the basic Resilience 101 program will be available to businesses and community organizations, and the emergency response program is geared toward individuals, families, and neighborhoods.

HCC’s initiative meshes with the City of Houston’s Resilient Houston, a strategy launched in 2020 that’s designed to protect Houston against disasters. As part of this strategy, the city has hired a chief resilience and sustainability officer, Priya Zachariah.

“Every action we take and investment we make should continue to improve our collective ability to withstand the unexpected shocks and disruptions when they arrive — from hurricanes to global pandemics, to extreme heat or extreme cold,” Mayor Sylvester Turner said last year. “The time is now to stop doing things the way we’ve always done them because the threats are too unpredictable.”

In an InnovationMap guest column published in February 2021, Richard Seline, co-founder of the Houston-based Resilience Innovation Hub, wrote that the focus of resilience initiatives should be pre-disaster risk mitigation.

“There is still work to be done from a legislative and governmental perspective, but more and more innovators — especially in Houston — are proving to be essential in creating a better future for the next historic disaster we will face,” Seline wrote.